articleThe LancetSep 25, 2008Closed access

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

AJAlan J. GarberRRRobert R. HenryRERobert E. RatnerPAPedro Alberto García-HernándezHRHiromi Rodriguez-Pattzi

Baylor College of Medicine · University of San Diego · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,052
total citations
FWCI
66.46
Percentile
100%
References
20
Citations per year

Authors

9

Topics & keywords

Topics
Keywords
  • Glimepiride
  • Medicine
  • Type 2 diabetes
  • Double blind
  • Liraglutide
  • Internal medicine
  • Lead (geology)
  • Diabetes mellitus
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding